Ruban Dhaliwal, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1174815245
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Radius Health, Inc. at 32.0% of the total. Reporting peaked in 2023 at $38,663 and has fallen 90.8% since, to $3,570 in 2025.
Across 97 payments — averaging $724.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Radius Health, Inc.$22K
- Ascendis Pharma Endocrinology Inc$18K
- Ultragenyx Pharmaceutical Inc.$12K
- Kyowa Kirin, Inc.$7K
- AstraZeneca$7K
- Amgen$3K
- plus $99 from 1 others
Across 52 payments — averaging $1461.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Radius Health, Inc.$41K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Amgen$9K
- Shire North American Group Inc$5K
- AstraZeneca$2K
What the payments were for
- Consulting fees$38,16654%
- Speaking & faculty fees$12,52718%
- Travel & lodging$7,55711%
- Food & beverage$2,3263%
- Education$9,65714%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Radius Health, Inc. | 40 | $22,494 |
| Ascendis Pharma Endocrinology Inc | 18 | $18,352 |
| Ultragenyx Pharmaceutical Inc. | 19 | $12,228 |
| Kyowa Kirin, Inc. | 8 | $6,927 |
| AstraZeneca(2 entities) | 8 | $6,875 |
| Amgen | 3 | $3,258 |
| Biomarin Pharmaceutical Inc. | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,232 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Ildiko LingvayDallas$711K
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.